Fundraising Fox
Mediwound
NASDAQ: MDWDYavne · Israel corporation · 6 known investors
Find your way into Mediwound
Sign up to see every warm intro you have to Mediwound
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Mediwound team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds. Its products include NexoBrid, an approved therapy for severe thermal burns, and EscharEx, a candidate for debridement of chronic and hard-to-heal wounds, serving hospitalized and wound care patients worldwide.
Founders & leadership
Board
Investors · 6
How we know: Deep Insight's portfolio page · Not right? Tell us
How we know: Gandyr Investments's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: a partner's Signal profile · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$30.5M disclosed across 2 rounds · 2022
▶$17.2MraisedOct 2022 · 10 investors · PharmaceuticalsRule 506(b)
- Yaron MeyerExecutive Officer
- Tzvi PalashExecutive Officer
- Vickie R. DriverDirector
- Nachum (Homi) ShamirDirector
- Sharon MalkaDirector
- Boaz Gur-LavieExecutive Officer
- Stephen T. WillsDirector
- Ety KlingerExecutive Officer, Director
- Assaf SegalDirector
- Ofer GonenExecutive Officer
- Lior RosenbergExecutive Officer
- Nissim MashiachDirector
- David FoxDirector
- Sharon KochanDirector
- Offering amount
- $17.2M
- Amount sold
- $17.2M
- Sales commissions
- $981.7K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Sep 2022
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
▶$13.3MraisedOct 2022 · 13 investors · PharmaceuticalsRule 506(b)
- Ety KlingerExecutive Officer, Director
- Ofer GonenExecutive Officer
- Boaz Gur-LavieExecutive Officer
- Sharon MalkaDirector
- Vickie R. DriverDirector
- Tzvi PalashExecutive Officer
- Nissim MashiachDirector
- Stephen T. WillsDirector
- Assaf SegalDirector
- Nachum (Homi) ShamirDirector
- Sharon KochanDirector
- David FoxDirector
- Yaron MeyerExecutive Officer
- Lior RosenbergExecutive Officer
- Offering amount
- $13.3M
- Amount sold
- $13.3M
- Sales commissions
- $928K
- Placement agents
- H.C. Wainwright & Co., LLC
- First sale
- Sep 2022
- Incorporated
- Corporation, Israel
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Mediwound.
Frequently asked questions
- What does Mediwound do?
- MediWound is a biotechnology company developing enzymatic treatments that selectively remove eschar tissue while preserving healthy tissue for burns and chronic wounds. Its products include NexoBrid, an approved therapy for severe thermal burns, and EscharEx, a candidate for debridement of chronic and hard-to-heal wounds, serving hospitalized and wound care patients worldwide.
- Who are Mediwound's investors?
- Mediwound's investors include Clal Biotechnology Industries, Deep Insight, Gandyr Investments, Israel Biotech Fund, New Era Capital Partners, Point72 Ventures.
- How much funding has Mediwound raised?
- Mediwound has disclosed $30.5M raised across 2 rounds.
- Where is Mediwound headquartered?
- Mediwound is headquartered in Yavne.